|
OALib Journal期刊
ISSN: 2333-9721
费用：99美元
|
|
|
|
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
DOI: 10.1080/2162402X.2019.1615817
A. Baron, A. Kaubisch, A. Pelusio, A.M. Leen, B. McFadden, C.J. Breitbach, D. Jonker, D. Shen, D.H. Kirn, F. Foerster, F. Habersetzer, G. Ungerechts, H. Wege, H.C. Lee, H.J. Yim, J. Heo, J.F. Blanc, J.M. Burke, J.M. Limacher, K.S. Byun, L. Ruo, M. Cho, M. Hennequi, M. Homerin, M. Lusky, M. Moehler, N. De Silva, N. Gaspar, N. Stojkowitz, O. Ebert, Olivier Rosmorduc, P. Merle, R. Lencioni, R. Patt, S.W. Paik, W.Y. Tak, Y. Chao
Keywords: Hepatocellular carcinoma, Pexa-Vec, sorafenib, oncolytic immunotherapy, oncolytic vaccinia
Abstract:
Full-Text
|
|
Contact Us
service@oalib.com QQ:3279437679 
WhatsApp +8615387084133
|
|
